A carregar...

Clinical Outcomes in Recurrent Glioblastoma with Bevacizumab therapy: An Analysis of the Literature

Bevacizumab (BEV) is a common treatment for recurrent glioblastoma (GBM). After progression on BEV, there is no consensus on subsequent therapy, as multiple chemotherapy trials have failed to demonstrate discernible activity for salvage. A previous review (995 patients) estimated a progression free...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Neurosci
Main Authors: Tipping, Matthew, Eickhoff, Jens, Robins, H. Ian
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581989/
https://ncbi.nlm.nih.gov/pubmed/28711289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jocn.2017.06.070
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!